



For us, the people living with serious diseases are, and must be, at the center of everything we do



AT EDITAS MEDICINE, THE FUTURE OF MEDICINE IS PERSONAL

We are pioneering what's possible. Our mission is to harness the potential of gene editing to develop medicines that transform the lives of people living with serious diseases around the world.

CRISPR/Cas12a gene-editing medicine

Editas has built a platform that utilizes CRISPR gene-editing technology, which stands for clustered regularly interspaced palindromic repeats. This technology can develop medicines that make specific changes to the DNA. By changing DNA, we have the **potential to treat the root causes of genetic diseases**—not just the symptoms.

WE CAN'T MAKE A LASTING IMPACT WITHOUT YOU

Editas looks to people living with genetic diseases, as well as their caregivers, to advise us. Editas is honored to support and learn from our community partners to better understand the serious diseases we aim to treat.



YOUR VOICE MATTERS

Together with our community partners, we work hard to understand and address unmet needs. We seek to improve the quality of life for individuals from historically underserved communities who are living with genetic diseases like sickle cell disease and beta thalassemia.



ADVISORY COUNCIL

In 2022, we established 2 advisory councils made up of patients and caregivers, all of whom continue to guide and advise us throughout the drug development journey for sickle cell disease and beta thalassemia.

"Thank you for including our voice, and thank you for listening to the community. It means a lot, and it's definitely appreciated." - Carla, Sickle Cell Disease Caregiver & Advocate

WE STRIVE TO REPRESENT THE COMMUNITIES WE SERVE



Editas is led by a diverse leadership team and board, each with their own passions for transformative, equitable, and inclusive care



The entire Editas team is diligent about facilitating a safe, inclusive, and collaborative culture that is committed to our communities and respectful of our environment.



We take ethnic and racial diversity to heart. Half of our employees in total, and half of senior management, are part of racially diverse communities.

Editas is committed to transforming the lives of people living with genetic diseases through both our science and our relationships with patients and their families

We recognize that communities of color experience sickle cell disease and beta thalassemia at higher rates than other communities. We also know the immense challenge that these serious diseases can have on the people living with them.



*Carla, Sickle Cell Disease Caregiver
Stephanie and Tristan
Living with Sickle Cell Disease*

**WE ARE DEDICATED TO DESIGNING TRANSFORMATIVE
MEDICINES TO IMPROVE QUALITY OF LIFE FOR THOSE
LIVING WITH SERIOUS DISEASES.**